Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Phase II Trial of CLAG-M in Relapsed ALL

CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.

Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood tests.

Inclusion Criteria:

• Relapsed or refractory acute lymphoblastic leukemia,
• Burkitts leukemia/lymphoma,
• Lymphoid blastic CML,
• Lymphoblastic lymphoma.